S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune
system in different ways and stop cancer cells from growing. It may also stop the growth of
cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving bortezomib together with thalidomide and
dexamethasone may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide
and dexamethasone works in treating patients with relapsed or refractory multiple myeloma.